AUPH - Company ID 0001600620
The table below shows Aurinia Pharmaceuticals Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $283.06M | $235.13M | $175.51M | $134.03M | $45.60M | $50.12M |
| Cost of revenue | $32.66M | $28.25M | $14.15M | $5.66M | $1.09M | $0.00 |
| Gross profit | - | - | - | - | - | - |
| R&D | $32.51M | $20.79M | $49.64M | $44.99M | $51.14M | $50.33M |
Aurinia Pharmaceuticals Inc. reported annual revenue of $283.06M for fiscal year 2025. That is up 20.4% from $235.13M in fiscal 2024. Over the 8 fiscal years shown, annual revenue grew from $463.00K (FY 2018) to $283.06M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $101.79M |
| $172.03M |
| $195.00M |
| $196.40M |
| $173.50M |
| $97.30M |
| Operating income | $104.91M | -$4.69M | -$91.69M | -$111.47M | -$180.74M | -$104.29M |
| Income tax | -$173.04M | $1.70M | $551.00K | $1.83M | $760.00K | -$94.00K |
| Net income | $287.20M | $5.80M | -$78.00M | -$108.20M | -$181.00M | -$102.68M |
| EPS (diluted) | $2.07 | $0.04 | -$0.54 | -$0.76 | -$1.40 | -$0.87 |